{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:10:55Z","timestamp":1771053055135,"version":"3.50.1"},"reference-count":81,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Status epilepticus (<jats:styled-content style=\"fixed-case\">SE<\/jats:styled-content>) has a high mortality rate and is one of the most common neurologic emergencies. Fast progression of this neurologic emergency and lack of response to traditional antiepileptic drugs (<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s) in most cases has challenged clinicians to use new agents. This article evaluates the efficacy and safety of <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s released to the market after 2000 for <jats:styled-content style=\"fixed-case\">SE<\/jats:styled-content>, refractory status epilepticus (<jats:styled-content style=\"fixed-case\">RSE<\/jats:styled-content>), and super\u2010refractory status epilepticus (<jats:styled-content style=\"fixed-case\">SRSE<\/jats:styled-content>). The PubMed database was searched for clinical trials published between January 2000 and July 2018 using the search terms <jats:italic>status epilepticus, refractory status epilepticus, super refractory status epilepticus, brivaracetam, clobazam, cannabidiol, eslicarbazepine, lacosamide, perampanel, rufinamide, stiripentol,<\/jats:italic> and <jats:italic>zonisamide<\/jats:italic>. Trials that evaluated these agents in adults with <jats:styled-content style=\"fixed-case\">SE<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> RSE<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">SRSE<\/jats:styled-content> were included. Brivaracetam use was identified in two retrospective reviews with success rates of 27% and 57%. One unsuccessful case report of cannabidiol use in <jats:styled-content style=\"fixed-case\">SE<\/jats:styled-content> was found. Four clobazam studies were identified in <jats:styled-content style=\"fixed-case\">SE<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">RSE<\/jats:styled-content> with success rates ranging from 25\u2013100%. No evidence for the use of eslicarbazepine and zonisamide was found. Using the search terms for lacosamide identified 38 articles: 1 systematic review, 5 prospective studies, 15 retrospective reviews, and 17 case reports. Success rates and dosing varied, but studies that included focal or partial types of <jats:styled-content style=\"fixed-case\">SE<\/jats:styled-content> showed higher success rates. Five articles were identified regarding perampanel use in this setting. Three were retrospective reviews with success rates ranging from 17\u201360%, and two were case reports. Only one case report regarding the use of rufinamide was found; rufinamide titrated up to 4.4\u00a0mg\/day allowed discontinuation of barbiturate and clobazam. One case report and two case series of stiripentol were found with reported efficacy between 60% and 100% in <jats:styled-content style=\"fixed-case\">SRSE<\/jats:styled-content>. Evidence is currently insufficient to support the use of these agents in this setting.<\/jats:p>","DOI":"10.1002\/phar.2229","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T23:16:58Z","timestamp":1549408618000},"page":"297-316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Use of Newer Anticonvulsants for the Treatment of Status Epilepticus"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2199-0552","authenticated-orcid":false,"given":"Salia","family":"Farrokh","sequence":"first","affiliation":[{"name":"Johns Hopkins Hospital Division of Critical Care and Surgery Pharmacy Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-2042","authenticated-orcid":false,"given":"John","family":"Bon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Summa Health System Akron Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2990-0259","authenticated-orcid":false,"given":"Michael","family":"Erdman","sequence":"additional","affiliation":[{"name":"University of Florida Health Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eljim","family":"Tesoro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice University of Illinois at Chicago Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-012-9695-z"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03622.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.4.1029"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.09.003"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr215"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0424-1"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14434"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0509-5"},{"key":"e_1_2_6_10_1","unstructured":"UCB Inc.Prescribing information Briviact (Brivaracetam). Smyrna GA;2016."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13787"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.03.028"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14486"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13212"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12432"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12433"},{"key":"e_1_2_6_17_1","unstructured":"Greenwich Biosciences Inc.Epidiolex [package insert]. Carlsbad CA;2018."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-018-0898-y"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.01.009"},{"key":"e_1_2_6_20_1","unstructured":"Lundbeck.Prescribing information Onfi (Clobazam). Deerfield IL;2014."},{"issue":"9","key":"e_1_2_6_21_1","first-page":"1058","article-title":"Effect of renal impairment on pharmacokinetics of clobazam","volume":"50","author":"Walzer M","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13013"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0724-y"},{"key":"e_1_2_6_24_1","unstructured":"Sunovion Pharmaceuticals Inc.Prescribing information Aptiom (Eslicarbazepine) package insert. Marlborough MA;2017."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.4137\/JCNSD.S4888"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.43600.x"},{"key":"e_1_2_6_27_1","unstructured":"UCB Inc.Prescribing information Vimpat (Lacosamide). Smyrna GA;2012."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2012.10.004"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.07.005"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.04.025"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-016-0322-2"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2013.07.011"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7133-6"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-011-9662-0"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.12.008"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03204.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01423.x"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01430.x"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-010-9501-8"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.01.017"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2013.03.005"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.03.010"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12935"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2017.46"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2014.12.001"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.04.045"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7487-4"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2013.12.004"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2013.0565"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31829b21ba"},{"issue":"4","key":"e_1_2_6_51_1","first-page":"255","article-title":"Refractory nonconvulsive status epilepticus","volume":"53","author":"Torres\u2010Cano N","year":"2011","journal-title":"Rev Neurol"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.02.008"},{"issue":"1","key":"e_1_2_6_53_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.33588\/rn.5301.2011241","article-title":"Intravenous lacosamide in monotherapy in a case of complex partial epileptic status","volume":"53","author":"Granda\u2010M\u00e9ndez J","year":"2011","journal-title":"Rev Neurol"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.02.006"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2010.11.004"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.10.012"},{"issue":"10","key":"e_1_2_6_57_1","first-page":"603","article-title":"The use of oral lacosamide in a patient with refractory partial epileptic status","volume":"50","author":"Turp\u00edn\u2010Fenoll L","year":"2010","journal-title":"Rev Neurol"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02256.x"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.12.009"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-013-9882-6"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2017.05.007"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.09.004"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-018-0560-6"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.03.018"},{"key":"e_1_2_6_65_1","unstructured":"Eisai Inc.Prescribing information Fycompa (perampanel). Revised 7\u20102017."},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-012-0021-2"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.04.005"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.01.036"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-013-0225-3"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2015.06.007"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14494"},{"issue":"1","key":"e_1_2_6_72_1","first-page":"S27","article-title":"Rufinamide from clinical trials to clinical practice in the United States and Europe","volume":"13","author":"Resnick T","year":"2011","journal-title":"Epileptic Disord"},{"key":"e_1_2_6_73_1","unstructured":"Eisai Inc.Prescribing information Banzel (rufinamide). Revised 6\u20102015"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620090-00007"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.04.003"},{"key":"e_1_2_6_76_1","unstructured":"Biocodex Inc.Stiripentol [package insert]. Beauvais France.2018."},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.12.020"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12403"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.08.1950"},{"key":"e_1_2_6_80_1","unstructured":"Concordia Pharmaceuticals.Prescribing information Zonegran (Zonisamide) package insert. St. Michael Barbados;2017"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(96)80104-X"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2016.1154534"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:13:33Z","timestamp":1761063213000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1002\/phar.2229"],"URL":"https:\/\/doi.org\/10.1002\/phar.2229","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2019-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}